Previously, the monomeric anti-EGFR Nanofitin B10 has shown high accumulation and broad diffusion in A431 tumor xenografts in immunodeficient mice, effectively targeting nearly all tumor cells as early as 90 min post-injection [13]. The gene discussed is EGFR; the disease is neoplasm.